Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 20;140(20):2127–2141. doi: 10.1182/blood.2022016040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 3. — Increased MCL1 expression at VEN relapse is only partially explained by amplification of the MCL1 gene. (A) Representation of the gained genomic regions in the 1q locus across the screening and relapsed samples from CLL12, CLL16, and CLL95 analyzed by WES. MCL1 is highlighted in red. Gray dotted lines indicate CN of 2. Blue lines indicate CN inferred from WES data. (B-D) UMAP projections (left) of CLL cells from (B) CLL12, (C) CLL16, and (D) CLL95 at relapse, with violin plots (right panels) showing inferred CN variation of 1q21 (MCL1) or relative expression of indicated prosurvival genes across the individual clusters. (E) Histograms showing mass cytometric analysis of MCL1 protein expression in viable (cisplatin^lo) CD5^+veCD19^+ve PBMCs from screening samples from CLL16 (blue), relapsed samples from CLL16, CLL12, and CLL95 (all red). (F) PBMCs prepared at VEN-relapse were incubated in vitro for 24 hours with 0 to 4 μM S63845 (MCL1i). Viability (PI^-ve) was measured in CLL cells (CD5^+veCD19^+ve), and data points represent the mean ± standard deviation of triplicate measurements in single experiments. CLL95 displayed marked sensitivity to MCL1i (LC50 10nM), while CLL12 and CLL16 had modest sensitivity (LC50s ∼600nM and ∼2700nM, respectively).

Figure 3. — Increased MCL1 expression at VEN relapse is only partially explained by amplification of the MCL1 gene. (A) Representation of the gained genomic regions in the 1q locus across the screening and relapsed samples from CLL12, CLL16, and CLL95 analyzed by WES. MCL1 is highlighted in red. Gray dotted lines indicate CN of 2. Blue lines indicate CN inferred from WES data. (B-D) UMAP projections (left) of CLL cells from (B) CLL12, (C) CLL16, and (D) CLL95 at relapse, with violin plots (right panels) showing inferred CN variation of 1q21 (MCL1) or relative expression of indicated prosurvival genes across the individual clusters. (E) Histograms showing mass cytometric analysis of MCL1 protein expression in viable (cisplatin^lo) CD5^+veCD19^+ve PBMCs from screening samples from CLL16 (blue), relapsed samples from CLL16, CLL12, and CLL95 (all red). (F) PBMCs prepared at VEN-relapse were incubated in vitro for 24 hours with 0 to 4 μM S63845 (MCL1i). Viability (PI^-ve) was measured in CLL cells (CD5^+veCD19^+ve), and data points represent the mean ± standard deviation of triplicate measurements in single experiments. CLL95 displayed marked sensitivity to MCL1i (LC50 10nM), while CLL12 and CLL16 had modest sensitivity (LC50s ∼600nM and ∼2700nM, respectively).